Whole Blood Metabolomic Profiling of Mice with Tacrolimus-Induced Chronic Nephrotoxicity: NAD<sup>+</sup> Depletion with Salvage Pathway Impairment

Tacrolimus (TAC)-induced chronic nephrotoxicity (TAC nephrotoxicity) is a serious issue for long-term graft survival in kidney transplantation. However, the pathophysiology of TAC nephrotoxicity remains unclear. In this study, we analyzed whole blood samples from mice that developed TAC nephrotoxici...

Full description

Saved in:
Bibliographic Details
Main Authors: Sho Nishida, Tamaki Ishima, Daiki Iwami, Ryozo Nagai, Kenichi Aizawa
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Antioxidants
Subjects:
Online Access:https://www.mdpi.com/2076-3921/14/1/62
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832589254656524288
author Sho Nishida
Tamaki Ishima
Daiki Iwami
Ryozo Nagai
Kenichi Aizawa
author_facet Sho Nishida
Tamaki Ishima
Daiki Iwami
Ryozo Nagai
Kenichi Aizawa
author_sort Sho Nishida
collection DOAJ
description Tacrolimus (TAC)-induced chronic nephrotoxicity (TAC nephrotoxicity) is a serious issue for long-term graft survival in kidney transplantation. However, the pathophysiology of TAC nephrotoxicity remains unclear. In this study, we analyzed whole blood samples from mice that developed TAC nephrotoxicity in order to discover its mechanism. Mice were divided into a TAC group and a control group (<i>n</i> = 5 per group). The TAC group received TAC subcutaneously (1 mg/kg/day for 28 days), while the control group received normal saline instead. After the administration period, whole blood was collected and metabolomic analysis was performed, revealing significant changes in 56 metabolites. The major metabolic changes were related to uremic toxins, vascular damage, and NAD<sup>+</sup>. NAD<sup>+</sup> levels were significantly lower in the TAC group, and ADP-ribose, nicotinamide, and nicotinamide N-oxide, which are degradation products of NAD<sup>+</sup>, were significantly higher, suggesting impairment of the NAD<sup>+</sup> salvage pathway. NAD<sup>+</sup> deficiency suggests cellular aging and mitochondrial dysfunction, which may induce vascular damage and chronic kidney disease. Our study demonstrated a correlation between low NAD<sup>+</sup> levels and the pathophysiology of TAC nephrotoxicity.
format Article
id doaj-art-49a77d1e708343cf870bdc6a500513b6
institution Kabale University
issn 2076-3921
language English
publishDate 2025-01-01
publisher MDPI AG
record_format Article
series Antioxidants
spelling doaj-art-49a77d1e708343cf870bdc6a500513b62025-01-24T13:19:21ZengMDPI AGAntioxidants2076-39212025-01-011416210.3390/antiox14010062Whole Blood Metabolomic Profiling of Mice with Tacrolimus-Induced Chronic Nephrotoxicity: NAD<sup>+</sup> Depletion with Salvage Pathway ImpairmentSho Nishida0Tamaki Ishima1Daiki Iwami2Ryozo Nagai3Kenichi Aizawa4Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Shimotsuke 329-0498, JapanDivision of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Shimotsuke 329-0498, JapanDivision of Renal Surgery and Transplantation, Department of Urology, Jichi Medical University, Shimotsuke 329-0498, JapanJichi Medical University, Shimotsuke 329-0498, JapanDivision of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Shimotsuke 329-0498, JapanTacrolimus (TAC)-induced chronic nephrotoxicity (TAC nephrotoxicity) is a serious issue for long-term graft survival in kidney transplantation. However, the pathophysiology of TAC nephrotoxicity remains unclear. In this study, we analyzed whole blood samples from mice that developed TAC nephrotoxicity in order to discover its mechanism. Mice were divided into a TAC group and a control group (<i>n</i> = 5 per group). The TAC group received TAC subcutaneously (1 mg/kg/day for 28 days), while the control group received normal saline instead. After the administration period, whole blood was collected and metabolomic analysis was performed, revealing significant changes in 56 metabolites. The major metabolic changes were related to uremic toxins, vascular damage, and NAD<sup>+</sup>. NAD<sup>+</sup> levels were significantly lower in the TAC group, and ADP-ribose, nicotinamide, and nicotinamide N-oxide, which are degradation products of NAD<sup>+</sup>, were significantly higher, suggesting impairment of the NAD<sup>+</sup> salvage pathway. NAD<sup>+</sup> deficiency suggests cellular aging and mitochondrial dysfunction, which may induce vascular damage and chronic kidney disease. Our study demonstrated a correlation between low NAD<sup>+</sup> levels and the pathophysiology of TAC nephrotoxicity.https://www.mdpi.com/2076-3921/14/1/62tacrolimus (TAC)TAC nephrotoxicityNAD<sup>+</sup>metabolomicschronic kidney disease biomarkersADMA
spellingShingle Sho Nishida
Tamaki Ishima
Daiki Iwami
Ryozo Nagai
Kenichi Aizawa
Whole Blood Metabolomic Profiling of Mice with Tacrolimus-Induced Chronic Nephrotoxicity: NAD<sup>+</sup> Depletion with Salvage Pathway Impairment
Antioxidants
tacrolimus (TAC)
TAC nephrotoxicity
NAD<sup>+</sup>
metabolomics
chronic kidney disease biomarkers
ADMA
title Whole Blood Metabolomic Profiling of Mice with Tacrolimus-Induced Chronic Nephrotoxicity: NAD<sup>+</sup> Depletion with Salvage Pathway Impairment
title_full Whole Blood Metabolomic Profiling of Mice with Tacrolimus-Induced Chronic Nephrotoxicity: NAD<sup>+</sup> Depletion with Salvage Pathway Impairment
title_fullStr Whole Blood Metabolomic Profiling of Mice with Tacrolimus-Induced Chronic Nephrotoxicity: NAD<sup>+</sup> Depletion with Salvage Pathway Impairment
title_full_unstemmed Whole Blood Metabolomic Profiling of Mice with Tacrolimus-Induced Chronic Nephrotoxicity: NAD<sup>+</sup> Depletion with Salvage Pathway Impairment
title_short Whole Blood Metabolomic Profiling of Mice with Tacrolimus-Induced Chronic Nephrotoxicity: NAD<sup>+</sup> Depletion with Salvage Pathway Impairment
title_sort whole blood metabolomic profiling of mice with tacrolimus induced chronic nephrotoxicity nad sup sup depletion with salvage pathway impairment
topic tacrolimus (TAC)
TAC nephrotoxicity
NAD<sup>+</sup>
metabolomics
chronic kidney disease biomarkers
ADMA
url https://www.mdpi.com/2076-3921/14/1/62
work_keys_str_mv AT shonishida wholebloodmetabolomicprofilingofmicewithtacrolimusinducedchronicnephrotoxicitynadsupsupdepletionwithsalvagepathwayimpairment
AT tamakiishima wholebloodmetabolomicprofilingofmicewithtacrolimusinducedchronicnephrotoxicitynadsupsupdepletionwithsalvagepathwayimpairment
AT daikiiwami wholebloodmetabolomicprofilingofmicewithtacrolimusinducedchronicnephrotoxicitynadsupsupdepletionwithsalvagepathwayimpairment
AT ryozonagai wholebloodmetabolomicprofilingofmicewithtacrolimusinducedchronicnephrotoxicitynadsupsupdepletionwithsalvagepathwayimpairment
AT kenichiaizawa wholebloodmetabolomicprofilingofmicewithtacrolimusinducedchronicnephrotoxicitynadsupsupdepletionwithsalvagepathwayimpairment